• Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing.
• The news provides a sigh of relief after the company said in August that the agency would need additional time to review the application. The original action date was Aug. 10.
• BTIG analyst Ryan Zimmerman, who rates Humacyte a buy, wrote that the development is a positive sign and "suggests that there is forward progress." And while he expects ATEV will win approval, he added the "timing is difficult to handicap."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.